Industry Insider - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Industry Insider
123
Next »

Campaign Against Counterfeit Drugs Continues

May 2, 2013
By: Nathan Jessop

Drug companies team up with INTERPOL to keep counterfeit medicines off the Internet and out of the hands of patients.

European Biotech Struggles to Thrive

April 2, 2013
By: Nathan Jessop

The outlook of the European biotech sector may not be as bleak as apparently believed despite the current economic climate, but compared with their US rivals, biotech companies are still struggling to attract investors and secure funding.

Can IMI Deliver Real Innovation for Europe?

March 1, 2013
By: Nathan Jessop

Has Europe's Innovative Medicines Initiative been successful in alleviating concerns regarding the region?s levels of pharmaceutical innovation?

Pharma Fights Healthcare Cost-Containment Policies

February 1, 2013
By: Nathan Jessop

The ongoing economic crisis in Europe has accelerated healthcare cost-containment measures targeting the price of pharmaceuticals, but the pharma industry is not giving in without a fight.

Manufacturing Misery in Vaccines

January 1, 2013
By: Nathan Jessop
Pharmaceutical Technology Europe

Vaccine manufacturing was predicted in 2008 to be on the cusp of a golden era, but instead the industry has experienced cost pressures, high-profile liability cases and production setbacks.

Germany's New Pricing Policy Loses Appeal with Pharma

December 2, 2012
By: Nathan Jessop
Pharmaceutical Technology

Nathan Jessop reviews the pharmaceutical industry's experience with the first year of Germany?s new pricing policy.

Regulatory Intervention in Paediatric Medicines

September 1, 2012
By: Nathan Jessop
Pharmaceutical Technology Europe

Regulators in both the EU and the US have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects?

Changing German Market Depresses the Pharma Industry

August 1, 2012
By: Nathan Jessop
Pharmaceutical Technology Europe

Germany has shifted from a market where the pharmaceutical industry could enjoy considerable pricing freedom to a sensitive market influenced by cost-containment policies.

Parallel Trade's Emerging Image Crisis

July 1, 2012
By: Nathan Jessop
Pharmaceutical Technology Europe

Parallel trade has frustrated pharmaceutical manufacturers for years and now evidence has linked such trade to drug shortages in Europe. Parallel trade representatives have yet to respond, but will need to react quickly to salvage their reputation.

123
Next »

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here